Sapanisertib

DB11836InvestigationalSmall molecule

Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase mTOR
Curator reviewed
Formula / weight: C₁₅H₁₅N₇O · 309.333 g/mol (avg)
Code names: INK-128 · MLN-0128 · TAK-228

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyGYLDXIAOMVERTK-UHFFFAOYSA-NSMILESCC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1

Targets

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

47Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sapanisertib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.